drugset
drugset / Trial / NCT00020709

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00020709 ↗

Phase 3 Completed 840 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of tumors. It is not yet known whether combination chemotherapy plus radiation therapy is more effective with or without gefitinib in treating non-small cell lung cancer

Timeline

Start
2001-06
Primary completion
2007-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — Oral
Background Cisplatin Other / unclassified — Intravenous
Background Docetaxel Small molecule — Intravenous
Background Etoposide Small molecule — Intravenous

Indications

lung adenocarcinoma lung large cell carcinoma squamous cell lung carcinoma